Jairam Eswara, MD
Urology · Brighton, MANPI 1659576189
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,850 of the $63,927 with a category attached, or 62.3%. 34 manufacturers reported payments, led by Covidien LP at 52.0% of the total. Among urology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $345.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$33K
- Johnson & Johnson$12K
- Intuitive Surgical$6K
- Medtronic$3K
- Gyrus ACMI, Inc.$3K
- Davol Inc.$2K
- plus $5K from 28 others
What the payments were for
- Consulting fees$39,85062%
- Speaking & faculty fees$10,04816%
- Travel & lodging$1,5252%
- Food & beverage$6,16710%
- Education$6,33710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 16 | $33,265 |
| Johnson & Johnson | 20 | $12,042 |
| Intuitive Surgical | 4 | $6,128 |
| Medtronic(2 entities) | 14 | $2,921 |
| Gyrus ACMI, Inc. | 1 | $2,500 |
| Davol Inc. | 1 | $2,000 |
| Boston Scientific | 17 | $1,128 |
| Astellas Pharma US Inc | 24 | $714 |
| Ferring Pharmaceuticals Inc. | 9 | $637 |
| Procept Biorobotics Corporation | 4 | $373 |
| Convatec Inc. | 7 | $240 |
| Merck | 9 | $225 |
| Endo Pharmaceuticals Inc. | 10 | $199 |
| AbbVie | 7 | $170 |
| Angiodynamics, Inc. | 1 | $166 |
| Sumitomo Pharma America, Inc. | 5 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Endo USA, Inc. | 5 | $123 |
| Seagen Inc. | 1 | $111 |
| Tempus AI, Inc | 3 | $84 |
| Urovant Sciences Inc | 4 | $84 |
| Laborie Medical Technologies Corp. | 1 | $70 |
| Teleflex LLC | 1 | $70 |
| Telix Pharmaceuticals | 3 | $68 |
| Pfizer | 3 | $54 |
| Neotract Inc. | 1 | $53 |
| Myriad Genetic Laboratories, Inc. | 3 | $47 |
| Coloplast | 2 | $47 |
| Acerus Pharmaceuticals Corporation | 3 | $41 |
| Myovant Sciences Inc. | 1 | $28 |
| Blue Earth Diagnostics | 1 | $24 |
| Amgen | 1 | $18 |
| Photocure Inc | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$9,125
- CARVYKTI$9,125
- Da Vinci Surgical System$6,000
- Soltive$2,500
- INTERSTIM$650
- ADSTILADRIN$515
- AquaBeam Robotic System$290
- Nanoknife$166
- Erleada$153
- SpaceOAR VUE System - 10mL$145
- FLEXIVA$131
- PADCEV$111
- AMS$106
How this compares
$63,927 in reported general payments places this provider in the 95th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 12 | $11,218 |
| Tamsulosin Hcl | 77 | $1,157 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $336 |
| Finasteride | 25 | $182 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $144 | $11,21812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 327 urology providers in Massachusetts.
Other urology in Brighton
- David StaskinBrighton$407K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Andrew KramerHyannis$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.